A single 100 micrograms dose of DT120, a specially formulated LSD-based drug, has shown rapid and lasting improvement in adults with major depressive disorder in a large phase 3 clinical trial.
- Single 100 µg dose reduces depression symptoms significantly
- Well tolerated with mostly mild, temporary side effects
- Advances potential new treatment for major depressive disorder
What happened
Definium Therapeutics conducted a groundbreaking phase 3 trial called Emerge, investigating the effectiveness of DT120 ODT, a fast-dissolving lysergide (LSD) formulation, in adults diagnosed with major depressive disorder (MDD). The study included 149 participants aged 18 to 74 across 20 sites, all meeting strict diagnostic criteria for MDD. Patients received a single 100 microgram dose of DT120 or a placebo, with results tracked over six weeks.
The trial met its primary endpoint by showing a significant reduction in depression scores compared to placebo, with an 8.1 point difference on the Montgomery-Åsberg Depression Rating Scale (MADRS). The treatment was well tolerated, with 99% of reported adverse effects being mild to moderate and generally limited to the dosing day. No new safety concerns, including suicidal ideation, were observed.
Why it feels good
This trial represents a major step forward in addressing the challenges many face with current depression treatments, which often require long-term medication, multiple dose adjustments, and come with troubling side effects. The ability to rapidly alleviate symptoms with just a single dose offers hope for faster relief and fewer complications.
Clinicians and patients alike are encouraged by the potential for DT120 to provide a robust, durable treatment option with a novel mechanism that works by engaging serotonin receptors in the brain. Its success also builds confidence in psychedelic-based therapies, which are gaining recognition for treating various mental health issues beyond depression.
What to enjoy or watch next
The promising Emerge trial is just the first of two phase 3 studies for DT120. The upcoming Ascend trial will further evaluate different doses, refining understanding of its efficacy and safety. Observers and patients can look forward to more detailed data that could shape future depression care standards.
DT120 is one among several new psychedelic-derived medications aiming to revolutionize mental health treatment. As Definium Therapeutics prepares for FDA submission, alongside similar developments from other companies, the coming years could see significant shifts in how depression and related disorders are treated around the world.